NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
On Nov. 19, 2003, a novel approach to treatment of solid cancers involved therapeutic agents that inhibit the…
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
On Dec. 12, 2002, the National Cancer Institute (NCI) announced that a clinical trial had shown that reducing…
On Mar. 26, 2005, The University of Southern California/Norris Comprehensive Cancer Center in Los Angeles announced a $15…
On Sept. 4. 2001, the National Cancer Institute (NCI) and the American College of Radiology Imaging Network launched…
On May 24, 2001, Dr. Eldon Jupe and a team of Oklahoma Medical Research Foundation (OMRF) researchers found…
On Jul. 28, 2000, President Bill Clinton signed into law the Semipostal Authorization Act (P.L. 106-253), which gave…
On May 25, 1999. the Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer…
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
In 1998, the Mammography Quality Standards Reauthorization Act (MQSA) was passed by the U.S. Congress and continued the…
In 1998, Tamoxifen, created with the MCF-7 breast cancer cell line established by Karmanos, was revealed to reduce…
On Aug. 13, 1997, the Stamp Out Breast Cancer Act (PL 105-41) was signed into law by President…
In August 1997, the U.S. Congress passed legislation that directed the U.S. Postal Service to issue its first…
In January 1996, the U.S. Food and Drug Administration (FDA) approved anastrozole (Arimidex) as a treatment for breast…
In 1995, The BRCA2 gene was mapped to chromosomal 13q. Just fifteen months later, Wooster et al. reported…
In 1995, scientists cloned the tumor suppressor genes BRCA1 and BRCA2, inherited genetic mutations that can predict an…
In 1995, Mary-Claire King, an internationally known human geneticist, was recruited to the University of Washington’s (UW) School…
On Oct. 7, 1994, a strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and…
In 1993, the Washington University School of Medicine announced that it was a participating site for the prostate,…
In 1993, Bristol-Myers Squibb launched TAXOL (paclitaxel). The company invested hundreds of millions of dollars to supply TAXOL…